Today, CELLINK launches the C.WASH, an innovative liquid handling system for media change in cellular assays and tipless magnetic bead washing. Among other workflows, the C.WASH will help with high-throughput COVID-19 testing and research. The C.WASH offers a non-contact method of performing complex washing tasks, enabling automated and highly reproducible washing of micro well plates using centrifugal forces. It improves workflows by reducing costs and saving time when performing high throughput screening, cell-based assays and magnetic bead based nucleic acid extractions.To bring the C.WASH to market, CELLINK has signed a license agreement with AusBio Laboratories Co Ltd. to use their technology in the system. The benchtop device will be exclusively distributed worldwide by the CELLINK group and will be sold under the cytena brand as part of the Liquid Handling & Bioprocessing business area. The C.WASH will further broaden CELLINK’s instrument portfolio for applications in drug discovery, single-cell analysis and next-generation sequencing.
“We are thrilled to be launching the C.WASH and partnering with AusBio. This is a great step forward for the Liquid Handling & Bioprocessing business area as we continue to break down barriers and provide our customers in the life science community with highly efficient workflows in high-throughput screening and library prep for sequencing.”
—Jonas Schöndube, Business Area Manager at CELLINK, CEO at cytena GmbH
For further information, please contact:
Erik Gatenholm, CEO Gusten Danielsson, CFO
Phone (Sweden): +46 73 267 00 00 Phone (Sweden): +46 70 991 86 04
Phone (US): +1 (650) 515 5566 Phone (US): +1 (857) 332 2138
Email: [email protected] Email: [email protected]
This information was submitted for publication, through the agency of the contact persons set out above, on October 21, 2020 at 11:30 CET.
About CELLINKFounded in 2016, CELLINK is a global life-science company that provides technologies, products and services to create, understand and master biology. With a focus on the application areas of bioprinting, analysis, and liquid handling and bioprocessing, the company develops and markets innovative technologies that enable researchers in the life sciences to culture cells in 3D, perform high-throughput drug screening and print human tissues and organs for the medical, pharmaceutical and cosmetic industries. CELLINK’s products are trusted b
y more than 1,800 laboratories, including ones at all the top 20 pharmaceutical companies, are being used in more than 60 countries, and have been cited in more than 200 publications. CELLINK is creating the future of medicine.Visit cellink.com to learn more. CELLINK is listed on the Nasdaq Stockholm Main Market under CLNK B.
About AusBio Laboratories Co Ltd.
Founded in 1992, AusBio is a veteran biotech company known for innovation and integration, with a focus on the development and commercialization of platform technologies for disease screening, diagnosis and monitoring across a variety of medical disciplines. AusBio has served over 2000 units of automated liquid handling instruments, covering majority of provincial and municipal blood banks, as well as clinical and forensic laboratories across China.
Visit www.ausbio.com to learn more.